ストックスクリーナーアプリを入手
6.31
6.19%
0.36
Trevi Therapeutics Inc (TRVI) 最新ニュース
Trevi Therapeutics Prices $100 Million Common Stock Offering - marketscreener.com
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock | TRVI Stock News - GuruFocus
Biotech Trevi Therapeutics Secures Major $100M Financing Through Stock Offering - Stock Titan
Trevi Therapeutics Announces Pricing Of $100 Million Underwritten Offering Of Common Stock - marketscreener.com
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - PR Newswire
H.C. Wainwright maintains Trevi Therapeutics stock rating following trial results - Investing.com Canada
Oppenheimer Raises Price Target for Trevi Therapeutics by $3 - Insider Monkey
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results - Insider Monkey
Stifel reiterates buy rating for Trevi Therapeutics stock after study results - Investing.com Canada
Oppenheimer Adjusts Price Target on Trevi Therapeutics to $23 From $20, Maintains Outperform Rating - marketscreener.com
Trevi Therapeutics stock soars to 52-week high of $7.43 By Investing.com - Investing.com South Africa
Trevi Therapeutics stock soars to 52-week high of $7.43 - Investing.com India
Trevi Therapeutics Terminates ATM Prospectus with Leerink - TipRanks
Oppenheimer raises Trevi Therapeutics stock price target to $23 By Investing.com - Investing.com UK
Trevi Therapeutics Plans $100 Million Stock Sale; Shares Sliding in After-Hours Trade - marketscreener.com
Oppenheimer Boosts Trevi Therapeutics (TRVI) Price Target to $23 | TRVI Stock News - GuruFocus
Trevi Therapeutics launches $100 million stock offering - Investing.com
Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Capital | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com
Trevi Therapeutics (TRVI) Launches $100M Public Offering | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Proposed Public Offering of Common Stock | TRVI Stock News - GuruFocus
Clinical-Stage Biotech Trevi Therapeutics Seeks $100M in Major Stock Offering with Morgan Stanley Leading - Stock Titan
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients - Benzinga
trevi therapeutics reports positive results from phase 2b cough trial By Investing.com - Investing.com Australia
Transcript : Trevi Therapeutics, Inc.Special Call - marketscreener.com
Trevi Therapeutics Reports Positive Phase 2b Trial Results - TipRanks
trevi therapeutics reports positive results from phase 2b cough trial - Investing.com
Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Ca - GuruFocus
Trevi Therapeutics Announces Positive Topline Results From Phase 2B Coral Trial Of Haduvio - marketscreener.com
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | TRVI Stock News - GuruFocus
Trevi Therapeutics (TRVI) Achieves Positive Results in Cough Treatment Trial | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough - Longview News-Journal
Trevi Therapeutics to Host Conference Call and Webcast on June 2 - GuruFocus
Critical Phase 2b Results Coming: Trevi's Novel IPF Chronic Cough Drug Could Change Treatment Landscape - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Analysts - Defense World
What is HC Wainwright’s Forecast for TRVI Q2 Earnings? - Defense World
H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating - MSN
Trevi Therapeutics to Participate in Upcoming June Conferences | - GuruFocus
Trevi Therapeutics to Participate in Upcoming June Conferences - Citizen Tribune
Trevi Therapeutics Reveals New Haduvio Data: Key Updates Coming at Major Medical Conferences - Stock Titan
Trevi Therapeutics (NASDAQ:TRVI) Coverage Initiated by Analysts at HC Wainwright - Defense World
H.C. Wainwright Commences Coverage on Trevi Therapeutics (TRVI) with Positive Outlook | TRVI Stock News - GuruFocus
H.C. Wainwright sets $21 target for Trevi Therapeutics stock By Investing.com - Investing.com Nigeria
HC Wainwright & Co. Initiates Coverage of Trevi Therapeutics (TRVI) with Buy Recommendation - Nasdaq
H.C. Wainwright sets $21 target for Trevi Therapeutics stock - Investing.com
HC Wainwright & Co. Initiates Coverage on Trevi Therapeutics (TRVI) with Buy Rating | TRVI Stock News - GuruFocus
Northern Trust Corp Raises Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from Needham & Company LLC - Defense World
Raymond James sets $29 target for Trevi Therapeutics stock By Investing.com - Investing.com Nigeria
Trevi Therapeutics (TRVI): Analyst Reiterates Buy Rating with $2 - GuruFocus
Stifel maintains Buy on Trevi Therapeutics, $15 target By Investing.com - Investing.com Nigeria
Trevi Therapeutics (TRVI): Analyst Reiterates Buy Rating with $24 Price Target | TRVI Stock News - GuruFocus
Trevi Therapeutics, Inc. Announces Additional Analyses from Phase 2A River Trial of Haduvio in Patients with Refractory Chronic Cough - marketscreener.com
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough - GuruFocus
Trevi Therapeutics Announces Additional Analyses from Phase 2a R - GuruFocus
Trevi Therapeutics (TRVI) Reveals New Findings from Phase 2a RIV - GuruFocus
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough | TRVI Stock News - GuruFocus
Trevi Therapeutics (TRVI) Reveals New Findings from Phase 2a RIVER Trial | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Additional Analyses From Phase 2A River Trial Of Haduvio In Patients With Refractory Chronic Cough - marketscreener.com
Prurigo Nodularis Market on Track for Major Expansion by 2034, According to DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
Price T Rowe Associates Inc. MD Has $104,000 Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Dimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
0.87%
0.19%
大文字化:
|
ボリューム (24 時間):